临床试验/NCT01243372

NCT01243372已完成不适用

Evaluating BRAF Mutations as Predictors of Efficacy in Cetuximab-Treated Colorectal Cancer Patients: A Retrospective Study of Tissues From CALGB / SWOG

Alliance for Clinical Trials in Oncology0 个研究点目标入组 1,142 人开始时间: 2009年11月最近更新: 2020年7月24日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: Alliance for Clinical Trials in Oncology
入组人数: 1,142
主要终点: Progression-free survival as measured by RECIST

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

RATIONALE: Studying samples of tissue in the laboratory from patients who received cetuximab may help doctors understand and predict how well patients will respond to treatment.

PURPOSE: This research study is studying biomarkers in predicting response to cetuximab in patients with advanced colorectal cancer.

详细描述

OBJECTIVES:

Primary

To determine, among patients with advanced CRC, whether the effect of treatment (cetuximab vs bevacizumab) on progression-free survival (PFS) depends on tumor BRAF V600E mutational status.

Secondary

To study the relationships between tumor BRAF V600E mutational status, OS, and tumor response.

研究设计

研究类型: Observational
观察模型: Case Only
时间视角: Retrospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

结局指标

主要结局

Progression-free survival as measured by RECIST

时间窗: Up to 36 months

次要结局

tumor response as measured by RECIST(Up to 36 months)
overall survival(Up to 36 months)

研究者

发起方

Alliance for Clinical Trials in Oncology

申办方类型

Other

责任方

Sponsor

相似试验

已完成

不适用

Immunoreactivity to Cetuximab in Cancer PatientsHead and Neck CancerColorectal Cancer

NCT00896896Vanderbilt-Ingram Cancer Center538

招募中

2 期

Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer StudyColorectal Cancer Metastatic

NCT06547203Sun Yat-sen University34

已完成

不适用

Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib TosylateLung Cancer

NCT01124669ECOG-ACRIN Cancer Research Group80

已完成

不适用

Biomarkers in Samples From Patients With Follicular Lymphoma Treated With RituximabLymphoma

NCT01150643Eastern Cooperative Oncology Group559

已完成

不适用

An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic MelanomaMalignant Melanoma

NCT02143999Hoffmann-La Roche403